Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — September 2022

Genmab — September 2022

Planlagt Fastgjort Låst Flyttet Genmab
509 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #60

    can't find anyting for Genmab in the ESMO abstracts - https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal/session/calendar?

    1 Reply Last reply
    0
    • StockBullS Offline
      StockBullS Offline
      StockBull
      wrote on sidst redigeret af
      #61

      US Consumer Price Index (CPI) 2022-09-13 12:30 PM vil afgøre retningen og SP500 skal ned og teste bunden fra Juni eller vidre op og teste ATH i 4800 sidst på året forudsat Q3 regnskaber er ok.

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #62

        https://oncologypro.esmo.org/meeting-resources/esmo-congress?event_resources_filter_form[search]=amivantamab amivantamab at ESMO

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #63

          1367P - JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study https://oncologypro.esmo.org/meeting-resources/esmo-congress/jnj-70218902-jnj-902-a-tmeff2-x-cd3-bispecific-antibody-in-prostate-cancer-initial-results-from-a-phase-i-dose-escalation-study

          1 Reply Last reply
          0
          • V Offline
            V Offline
            Vitus
            wrote on sidst redigeret af
            #64

            Uha, sikke en flot slutspurt af Genmab. Og vi kom godt forbi 2660, så kører toget jo nok opad….

            1 Reply Last reply
            0
            • P Offline
              P Offline
              peter12
              wrote on sidst redigeret af
              #65

              Inside information https://www.youtube.com/watch?v=bP6vpL_kDmg

              1 Reply Last reply
              0
              • V Offline
                V Offline
                Vitus
                wrote on sidst redigeret af
                #66

                1/3 af dagens omsætning handel i lukkeauktion…er kursen aftalt på forhånd …

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  ProinvestorNEWS
                  wrote on sidst redigeret af
                  #67

                  Genmab to Present at Morgan Stanley 20th Annual Global Healthcare Conference
                  https://www.proinvestor.com/investornyt/875462/genmab-to-present-at-morgan-stanley-20th-annual-global-healthcare-conference

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gdn55
                    wrote on sidst redigeret af
                    #68

                    Ja, ingen tvivl om det. Af en eller anden grund, fik de banker, fonde, o.s.v lov til at handle anonymt. Før de fik lov til dette kunne man se hvad de solgte , eller købte. Dette var spændende at følge. når en bank var kommet med en kæmpe købs anbefaling, var det da mærkeligt at de selv solgte. Jeg er sikker på der er aftaler mellem mange af de store banker, fonde o.s.v. Hvorfor vil man være anonym?

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #69

                      Tirsdagens aktier: Vestas og Ørsted lider under faldende gaspriser
                      https://www.proinvestor.com/investornyt/875492/tirsdagens-aktier-vestas-og-orsted-lider-under-faldende-gaspriser

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #70

                        Just a moment...

                        favicon

                        (www.fiercebiotech.com)

                        1 Reply Last reply
                        0
                        • V Offline
                          V Offline
                          Vitus
                          wrote on sidst redigeret af
                          #71

                          Til Pensionisten…jeg synes det er en underlig kommentar…..

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #72

                            Just a moment...

                            favicon

                            (firstwordpharma.com)

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #73

                              Standing out from existing treatments like it because of its administration as a one-hour infusion every six months after the first dose, ublituximab could see that distinction potentially proving a detriment

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #74

                                Some key opinion leaders (KOLs) in neurology have said in a recent FirstWord Therapy Trends report that they would be hesitant to prescribe a rapid-infusion therapy because of negative experiences in patients receiving Roche’s Ocrevus (ocrelizumab) in its two-hour, twice-yearly infusion time, approved by the FDA in 2020.

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #75

                                  Some KOLs also pointed to the convenience of Novartis’ Kesimpta (ofatumumab) and its subcutaneous administration as possibly raining on ublituximab’s major selling point.

                                  1 Reply Last reply
                                  0
                                  • SolsenS Offline
                                    SolsenS Offline
                                    Solsen
                                    wrote on sidst redigeret af
                                    #76

                                    Olie og gas får en over nakken. Mon ikke aktiemarkedet godt kan lide det 🙂

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #77

                                      Aktiemarkedet kan ikke lide prisfaldet på olie- og gas.

                                      1 Reply Last reply
                                      0
                                      • Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktør
                                        wrote on sidst redigeret af
                                        #78

                                        Det går hårdt ud over aktierne i sektoren.

                                        1 Reply Last reply
                                        0
                                        • V Offline
                                          V Offline
                                          Vitus
                                          wrote on sidst redigeret af
                                          #79

                                          Jo jo, godt vi så,ikke har aktier i sektoren lige nu….

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper